Universal testing and treatment as an HIV prevention strategy: research questions and methods

Richard Hayes, Kalpana Sabapathy, Sarah Fidler, Richard Hayes, Kalpana Sabapathy, Sarah Fidler

Abstract

Achieving high coverage of antiretroviral treatment (ART) in resource-poor settings will become increasingly difficult unless HIV incidence can be reduced substantially. Universal voluntary counselling and testing followed by immediate initiation of ART for all those diagnosed HIV-positive (universal testing and treatment, UTT) has the potential to reduce HIV incidence dramatically but would be very challenging and costly to deliver in the short term. Early modelling work in this field has been criticised for making unduly optimistic assumptions about the uptake and coverage of interventions. In future work, it is important that model parameters are realistic and based where possible on empirical data. Rigorous research evidence is needed before the UTT approach could be considered for wide-scale implementation. This paper reviews the main areas that need to be explored. We consider in turn research questions related to the provision of services for universal testing, services for immediate treatment of HIV-positives and the population-level impact of UTT, and the research methods that could be used to address these questions. Ideally, initial feasibility studies should be carried out to investigate the acceptability, feasibility and uptake of UTT services. If these studies produce promising results, there would be a strong case for a cluster-randomised trial to measure the impact of a UTT intervention on HIV incidence, and we consider the main design features of such a trial.

References

    1. World Health Organization, UNAIDS. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. WHO 2009 Progress Report. Available at: . [Accessed July 25, 2011].
    1. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS. 2010;24(5):621–35.
    1. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562 ):657–66.
    1. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562 ):643–56.
    1. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11 ):e298.
    1. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346(8974 ):530–6.
    1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23 ):2209–20.
    1. Mayaud P, Legoff J, Weiss HA, et al. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. J Infect Dis. 2009;200(2 ):216–26.
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996 ):1168–74.
    1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27 ):2587–99.
    1. FEM-PreP Project: Study to assess the role of Truvada in preventing HIV acquisition in women. FHI 360 2011. Avaiable at: . [Accessed July 25, 2011].
    1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657 ):48–57.
    1. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301(22 ):2380–2.
    1. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS. 2010;24(5 ):729–35.
    1. Garnett GP, Baggaley RF. Treating our way out of the HIV pandemic: could we would we should we? Lancet. 2009;373(9657 ):9–11.
    1. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368(9534 ):531–6.
    1. Dias Lima V, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis. 2008;198(1 ):59–67.
    1. Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets Infect Disord. 2003;3(4 ):345–53.
    1. Baggaley RF, Fraser C. Modelling sexual transmission of HIV: testing the assumptions, validating the predictions. Curr Opin HIV AIDS. 2010;5(4 ):269–76.
    1. Zachariah R, Harries AD, Philips M, et al. Antiretroviral therapy for HIV prevention: many concerns and challenges, but are there ways forward in sub-Saharan Africa? Trans R Soc Trop Med Hyg. 2010;104(6 ):387–91.
    1. Wagner B, Blower S. Costs of eliminating HIV in South Africa have been underestimated. Lancet. 2010;376(9745 ):953–4.
    1. Wagner BG, Kahn JS, Blower S. Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy? AIDS. 2010;24(5 ):775–6.
    1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011. [Accessed July 27, 2011]. Available at: .
    1. De Cock KM, Bunnell R, Mermin J. Unfinished business--expanding HIV testing in developing countries. N Engl J Med. 2006;354(5 ):440–2.
    1. Wolff B, Nyanzi B, Katongole G, Ssesanga D, Ruberantwari A, Whitworth J. Evaluation of a home-based voluntary counselling and testing intervention in rural Uganda. Health Policy Plan. 2005;20(2 ):109–16.
    1. Day S, Lakhani D, Hankins M, Rodgers CA. Improving uptake of HIV testing in patients with a confirmed STI. Int J STD AIDS. 2004;15(9 ):626–8.
    1. Mahto M, Higgins SP. Increased uptake of HIV screening following introduction of “opt out” testing and results by telephone. Sex Transm Infect. 2004;80(2):156.
    1. Mermin J, Bunnell R, Lule J, et al. Developing an evidence-based, preventive care package for persons with HIV in Africa. Trop Med Int Health. 2005;10(10 ):961–70.
    1. Rotheram-Borus MJ, Leibowitz AA, Etzel MA. Routine, rapid HIV testing. AIDS Educ Prev. 2006;18(3 ):273–80.
    1. Corbett EL, Dauya E, Matambo R, et al. Uptake of workplace HIV counselling and testing: a cluster-randomised trial in Zimbabwe. PLoS Med. 2006;3(7 ):e238.
    1. Burke Johnson R, Onwuegbuzie AJ. Mixed Methods Research: A Research Paradigm Whose Time Has Come. Educational Researcher. 2004;33(7 ):14–26.
    1. Lugada E, Levin J, Abang B, et al. Comparison of home and clinic-based HIV testing among household members of persons taking antiretroviral therapy in Uganda: results from a randomized trial. J Acquir Immune Defic Syndr. 2010;55(2 ):245–52.
    1. Sweat M, Morin S, Celentano D, et al. Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis. 2011;11(7 ):525–32.
    1. Callaghan M, Ford N, Schneider H. A systematic review of task- shifting for HIV treatment and care in Africa. Hum Resour Health. 2010;8:8.
    1. Pavie J, Rachline A, Loze B, et al. Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting. PLoS One. 2010;5(7):e11581.
    1. Chen MY, Bilardi JE, Lee D, Cummings R, Bush M, Fairley CK. Australian men who have sex with men prefer rapid oral HIV testing over conventional blood testing for HIV. Int J STD AIDS. 2010;21(6 ):428–30.
    1. Choko A, Desmond N, Webb E, et al. Feasibility, Accuracy, and Acceptability of Using Oral HIV Test Kits for Supervised Community-level Self-testing in a Resource-poor High-HIV Prevalence Setting: Blantyre, Malawi. 18th Conference on Retroviruses and Opportunistic Infections, 2011 Feb; 27- Mar. 2; Boston, USA. Abstract 42.
    1. Coetzee D, Hilderbrand K, Goemaere E, Matthys F, Boelaert M. Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop Med Int Health. 2004;9(6 ):A11–5.
    1. van der Merwe K, Chersich MF, Technau K, Umurungi Y, Conradie F, Coovadia A. Integration of antiretroviral treatment within antenatal care in Gauteng Province, South Africa. J Acquir Immune Defic Syndr. 2006;43(5 ):577–81.
    1. April MD. Rethinking HIV exceptionalism: the ethics of opt-out HIV testing in sub-Saharan Africa. Bull World Health Organ. 2010;88(9 ):703–8.
    1. Leon N, Naidoo P, Mathews C, Lewin S, Lombard C. The impact of provider-initiated (opt-out) HIV testing and counseling of patients with sexually transmitted infection in Cape Town, South Africa: a controlled trial. Implement Sci. 2010;5:8.
    1. Nakibinge S, Maher D, Katende J, Kamali A, Grosskurth H, Seeley J. Community engagement in health research: two decades of experience from a research project on HIV in rural Uganda. Trop Med Int Health. 2009;14(2 ):190–5.
    1. Beaudoin CE. HIV prevention in sub-Saharan Africa: a multilevel analysis of message frames and their social determinants. Health Promot Int. 2007;22(3 ):198–206.
    1. Johnson D, Flora JA, Rimal RN. HIV/AIDS public service announcements around the world: a descriptive analysis. J Health Commun. 1997;2:223–34.
    1. Lugada E, Millar D, Haskew J, et al. Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya. PLoS One. 2010;5(8 ):e12435.
    1. Anderson DA, Crowe SM, Garcia M. Point-of-care testing. Curr HIV/AIDS Rep. 2011;8(1 ):31–7.
    1. Gray RH, Makumbi F, Serwadda D, et al. Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. BMJ. 2007;335(7612 ):188.
    1. Anzala O, Sanders EJ, Kamali A, et al. Sensitivity and specificity of HIV rapid tests used for research and voluntary counselling and testing. East Afr Med J. 2008;85(10 ):500–4.
    1. Kagulire SC, Opendi P, Stamper PD, et al. Field evaluation of five rapid diagnostic tests for screening of HIV-1 infections in rural Rakai, Uganda. Int J STD AIDS. 2011;22(6 ):308–9.
    1. Ma ZM, Stone M, Piatak M, Jr, et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol. 2009;83(7 ):3288–97.
    1. Pao D, Fisher M, Hue S, et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS. 2005;19(1 ):85–90.
    1. Sagar M. HIV-1 transmission biology: selection and characteristics of infecting viruses. J Infect Dis. 2010;202(Suppl 2 ):S289–96.
    1. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191(9 ):1403–9.
    1. Pilcher CD, Tien HC, Eron JJ, Jr, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189(10 ):1785–92.
    1. Fidler S, Fox J, Porter K, Weber J. Primary HIV infection: to treat or not to treat? Curr Opin Infect Dis. 2008;21(1 ):4–10.
    1. Sagar M, Laeyendecker O, Lee S, et al. Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis. 2009;199(4 ):580–9.
    1. Hayes RJ, White RG. Amplified HIV transmission during early-stage infection. J Infect Dis. 2006;193(4 ):604–5. author reply 5-6.
    1. Everett DB, Baisely KJ, McNerney R, et al. Association of schistosomiasis with false-positive HIV test results in an African adolescent population. J Clin Microbiol. 2010;48(5 ):1570–7.
    1. Beelaert G, Fransen K. Evaluation of a rapid and simple fourth-generation HIV screening assay for qualitative detection of HIV p24 antigen and/or antibodies to HIV-1 and HIV-2. J Virol Methods. 2010;168(1-2 ):218–22.
    1. Juusola L, Brandeau ML, Long EF, Owens DK, Bendavid E. The Cost-Effectiveness of Symptom-Based Testing and Routine Screening for Acute HIV Infection in Men Who Have Sex with Men in the United States. AIDS. 2011. Jul 8, [Epub ahead of print]
    1. Obermeyer CM, Osborn M. The utilization of testing and counseling for HIV: a review of the social and behavioral evidence. Am J Public Health. 2007;97(10 ):1762–74.
    1. Koo DJ, Begier EM, Henn MH, Sepkowitz KA, Kellerman SE. HIV counseling and testing: less targeting, more testing. Am J Public Health. 2006;96(6 ):962–4.
    1. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14 ):1–17. quiz CE1-4.
    1. Matambo R, Dauya E, Mutswanga J, et al. Voluntary counseling and testing by nurse counselors: what is the role of routine repeated testing after a negative result? Clin Infect Dis. 2006;42(4 ):569–71.
    1. Denison JA, O'Reilly KR, Schmid GP, Kennedy CE, Sweat MD. HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990-2005. AIDS Behav. 2008;12(3 ):363–73.
    1. Corbett EL, Makamure B, Cheung YB, et al. HIV incidence during a cluster-randomized trial of two strategies providing voluntary counselling and testing at the workplace, Zimbabwe. AIDS. 2007;21(4 ):483–9.
    1. World Health Organization. Scaling-up HIV testing and counseling services: A toolkit for programme managers. WHO . Available at: . 2005. [Accessed July 25, 2011].
    1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision. WHO. Available at: . 2010. [Accessed July 25, 2011].
    1. Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010;51(4 ):392–400.
    1. waqqas s. PlusNews. SOUTH AFRICA: National HIV testing campaign disappoints. PlusNews. 2010. [Accessed July 25, 2011]. Available at: .
    1. Posse M, Meheus F, van Asten H, van der Ven A, Baltussen R. Barriers to access to antiretroviral treatment in developing countries: a review. Trop Med Int Health. 2008;13(7 ):904–13.
    1. Decroo T, Telfer B, Biot M, et al. Distribution of Antiretroviral Treatment Through Self-Forming Groups of Patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr. 2011;56(2 ):e39–44.
    1. Jaffar S, Amuron B, Foster S, et al. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet. 2009;374(9707 ):2080–9.
    1. Medley A, Garcia-Moreno C, McGill S, Maman S. Rates barriers and outcomes of HIV serostatus disclosure among women in developing countries: implications for prevention of mother-to-child transmission programmes. Bull World Health Organ. 2004;82(4 ):299–307.
    1. Howard AA, El-Sadr WM. Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned. Clin Infect Dis. 2010;50(Suppl 3 ):S238–44.
    1. Tudor Car L, van-Velthoven MH, Brusamento S, et al. Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries. (CD008741).Cochrane Database Syst Rev. 2011;6
    1. O'Brien D, Greig J, Sabapathy K, Shanks L. Comparison of integrated and vertical antiretroviral treatment programme outcomes in nine countries in Sub-Saharan Africa. XVIII International AIDS Conference; 2010 July 18-23; Vienna, Austria. Abstract WEAE0101.
    1. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4 ):251–61.
    1. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18 ):1815–26.
    1. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672 ):1352–63.
    1. Shepherd BE, Jenkins CA, Rebeiro PF, et al. Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Epidemiology. 2010;21(5 ):698–705.
    1. Jain V, Deeks SG. When to start antiretroviral therapy. Curr HIV/AIDS Rep. 2010;7(2 ):60–8.
    1. Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. (CD008272).Cochrane Database Syst Rev. 2010;3
    1. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4(5 ):e5575.
    1. Williams BG, Hargrove JW, Humphrey JH. The benefits of early treatment for HIV. AIDS. 2010;24(11 ):1790–1.
    1. US National Institutes of Health. Strategic Timing of Antiretroviral Treatment. Clinical Trials Feeds, updated. Available at: . 2011. Jun 30, [Accessed July 26, 2011].
    1. Nachega JB, Trotta MP, Nelson M, Ammassari A. Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications. Curr HIV/AIDS Rep. 2009;6(3 ):121–9.
    1. Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5(10 ):563–73.
    1. D'Andrea G, Brisdelli F, Bozzi A. AZT: an old drug with new perspectives. Curr Clin Pharmacol. 2008;3(1 ):20–37.
    1. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS. 2005;19(5 ):463–71.
    1. Watts DH. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep. 2007;4(3 ):135–40.
    1. Hsu H, Rydzak C, Cotich K, et al. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med. 2011;12(2 ):97–108.
    1. Ford N, Mofenson L, Kranzer K, et al. . Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS. 2010;24(10 ):1461–70.
    1. Campaign for Access to Essential Medicines. Untangling the Web of Antiretroviral Price Reductions. Available at: 2011. [Accessed July 25, 2011].
    1. Peter T, Blair D, Reid M, Justman J. DART and laboratory monitoring of HIV treatment. Lancet. 2010;375(9719 ):979.
    1. BiotechBistro Forums. Zyomyx point-of-care CD4 test selected by CD4 initiative to help treat HIV/AIDS. Avaiable at: . [Accessed July 25, 2011].
    1. Pham PA. Antiretroviral adherence and pharmacokinetics: review of their roles in sustained virologic suppression. AIDS Patient Care STDs. 2009;23(10 ):803–7.
    1. Bartlett JA, Buda JJ, von Scheele B, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr. 2006;41(3 ):323–31.
    1. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22 ):2283–96.
    1. Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008;197(8 ):1145–55.
    1. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8 ):1133–44.
    1. Burman W, Grund B, Neuhaus J, et al. Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial. J Acquir Immune Defic Syndr. 2008;49(2 ):142–50.
    1. Rieder P, Joos B, von Wyl V, et al. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS. 2010;24(8 ):1177–83.
    1. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):e11068.
    1. Potter D, Goldenberg RL, Chao A, et al. Do targeted HIV programs improve overall care for pregnant women?: Antenatal syphilis management in Zambia before and after implementation of prevention of mother-to-child HIV transmission programs. J Acquir Immune Defic Syndr. 2008;47(1 ):79–85.
    1. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses. 2001;17(10 ):901–10.
    1. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr. 2002;29(3 ):275–83.
    1. Vergidis PI, Falagas ME, Hamer DH. Meta-analytical studies on the epidemiology, prevention, and treatment of human immunodeficiency virus infection. Infect Dis Clin North Am. 2009;23(2 ):295–308.
    1. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731 ):2092–8.
    1. Graham SM, Holte SE, Peshu NM, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS. 2007;21(4 ):501–7.
    1. Fiore JR, Suligoi B, Saracino A, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS. 2003;17(15 ):2169–76.
    1. Nagot N, Ouedraogo A, Weiss HA, et al. Longitudinal effect following initiation of highly active antiretroviral therapy on plasma and cervico-vaginal HIV-1 RNA among women in Burkina Faso. Sex Transm Infect. 2008;84(3 ):167–70.
    1. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis. 2010;51(6 ):725–31.
    1. Walensky RP, Ciaranello AL, Park JE, Freedberg KA. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis. 2010;51(1 ):85–92.
    1. Hayes RJ, Moulton LH. Cluster randomised trials. Boca Raton: Chapman and Hall; 2009.
    1. Hayes RJ, Alexander NDE, Bennett S, Cousens SN. Design and analysis issues in cluster-randomized trials of interventions against infectious diseases. Stat Methods Medical Res. 2000;9:95–116.
    1. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep. 2011;8(1):62–72.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe